🎉 M&A multiples are live!
Check it out!

Acrivon Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Acrivon Therapeutics and similar public comparables like Pharming, Galapagos, and Julphar.

Acrivon Therapeutics Overview

About Acrivon Therapeutics

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.


Founded

2018

HQ

United States of America
Employees

78

Website

acrivon.com

Financials

LTM Revenue $48K

LTM EBITDA n/a

EV

-$129M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Acrivon Therapeutics Financials

Acrivon Therapeutics has a last 12-month revenue of $48K and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Acrivon Therapeutics achieved revenue of n/a and an EBITDA of -$88.2M.

Acrivon Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Acrivon Therapeutics valuation multiples based on analyst estimates

Acrivon Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$66.6M -$88.2M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$31.2M -$60.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Acrivon Therapeutics Stock Performance

As of April 15, 2025, Acrivon Therapeutics's stock price is $2.

Acrivon Therapeutics has current market cap of $47.0M, and EV of -$129M.

See Acrivon Therapeutics trading valuation data

Acrivon Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$129M $47.0M XXX XXX XXX XXX $-2.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Acrivon Therapeutics Valuation Multiples

As of April 15, 2025, Acrivon Therapeutics has market cap of $47.0M and EV of -$129M.

Acrivon Therapeutics's trades at -2692.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Acrivon Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Acrivon Therapeutics and 10K+ public comps

Acrivon Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$129M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.5x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Acrivon Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Acrivon Therapeutics Valuation Multiples

Acrivon Therapeutics's NTM/LTM revenue growth is 1672%

Acrivon Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Acrivon Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Acrivon Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Acrivon Therapeutics and other 10K+ public comps

Acrivon Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 32% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Acrivon Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Acrivon Therapeutics M&A and Investment Activity

Acrivon Therapeutics acquired  XXX companies to date.

Last acquisition by Acrivon Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Acrivon Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Acrivon Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Acrivon Therapeutics

When was Acrivon Therapeutics founded? Acrivon Therapeutics was founded in 2018.
Where is Acrivon Therapeutics headquartered? Acrivon Therapeutics is headquartered in United States of America.
How many employees does Acrivon Therapeutics have? As of today, Acrivon Therapeutics has 78 employees.
Who is the CEO of Acrivon Therapeutics? Acrivon Therapeutics's CEO is Mr. Peter Blume-Jensen, M.D.,PhD.
Is Acrivon Therapeutics publicy listed? Yes, Acrivon Therapeutics is a public company listed on NAS.
What is the stock symbol of Acrivon Therapeutics? Acrivon Therapeutics trades under ACRV ticker.
When did Acrivon Therapeutics go public? Acrivon Therapeutics went public in 2022.
Who are competitors of Acrivon Therapeutics? Similar companies to Acrivon Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Acrivon Therapeutics? Acrivon Therapeutics's current market cap is $47.0M
What is the current revenue of Acrivon Therapeutics? Acrivon Therapeutics's last 12-month revenue is $48K.
What is the current EV/Revenue multiple of Acrivon Therapeutics? Current revenue multiple of Acrivon Therapeutics is -2692.7x.
Is Acrivon Therapeutics profitable? Yes, Acrivon Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.